简
繁
EN
简
繁
EN
HOME
·
HENLIUS
Henlius (02696.HK): Self-Developed KAT6A/B Inhibitor HLX97 Approved for Clinical Trial
Tags:
HENLIUS
02696.HK
new drug launch
2026-03-05
HENLIUS(02696.HK): Enters into License Agreement with Eisai, Authorizing Commercialization of Hansoh® for Oncology Indications in Japan
Tags:
HENLIUS
02696.HK
2026-02-05
HENLIUS(02696.HK): Completes H-Share Full Circulation, 182.65 Million Unlisted Shares Converted to H-Shares to List Tomorrow
Tags:
HENLIUS
02696.HK
2026-02-04
Featured News
Finance
AcroMeta Signs Joint Venture Agreement to Advance Commercialization of AI Global Trade Platform "ZhiMao"
Finance
Sakae Holdings Proposes to Acquire Pastry Supplier Cooking Art Industries for S$741000
Finance
Ascent Bridge Proposes to Sell Loss-Making Subsidiary MTBL CC for Approximately S$59500
Finance
Nanyang New Development Terminates Investment and Shareholders’ Agreement Signed in February
Finance
Tritech Group Plans to Raise S$3 Million, Allotting New Shares in Three Tranches with Dual Options
ETF
Rapid Growth in Humanoid Robot Shipments Expected,GF China Science And Technology Innovation Board Artificial Intelligence ETF(588760) Rises 0.43% Intraday
ETF
China Universal CSI Consumer Staples ETF(159928) Falls 1.19% Intraday,Institution Notes Fading Spring Festival Consumption Boost and Weakening Catering Chain Recovery
ETF
Rising Demand Boosts Confidence,Guotai CSI Semiconductor Material Equipment Theme ETF(159516) Rises 0.50% Intraday
ETF
E Fund CSI Technology 50 ETF(159807) Rises 0.58% Intraday,Institution: Mixed Long-Short Expectations for the Sector in April
ETF
Low Volatility Coexists with Resilient Uplift,Maxwealth CSI Shanghai-Shenzhen-Hong Kong Gold Industry Commodity ETF(517520) Falls 0.89% Intraday
Scan QR Code
Download App